US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.09

-0.9324-1.50%

Volume:6K

Turnover:357.10K

Market Cap:287.12M

PE:19.98

High:62.20

Open:62.20

Low:61.06

Close:62.02

52wk High:64.10

52wk Low:39.76

Shares:4.70M

Float Shares:4.70M

Volume Ratio:0.30

T/O Rate:0.12%

Dividend:1.53

Dividend Rate:2.50%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study

THOMSON REUTERS

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS

Guardant Health initiated with a Buy at Rothschild & Co Redburn

China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily

Medical Device Inspection Campaign Launched by Ningyang County Market Regulators

MedTech Firm Joins Hong Kong Market: Evaluating MEDCAPTAIN's (02041) True Investment Potential

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

NEJM publishes Phase 1/2 clinical data on daraxonrasib

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PTH/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.09,"timestamp":1789747539760,"preClose":62.0224,"halted":0,"volume":5818,"delay":0,"changeRate":-0.015033278299453006,"floatShares":4700000,"shares":4700000,"eps":3.057033,"marketStatus":"Trading","change":-0.9324,"latestTime":"09-18 12:07:55 EDT","open":62.1967,"high":62.1967,"low":61.06,"amount":357097.08764,"amplitude":0.018327,"askPrice":61.19,"askSize":400,"bidPrice":61.09,"bidSize":92,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.0224,"sharesOutstanding":2480000,"nav":60.77493,"aum":287465418.9,"dividendRate":0.024975,"bidAskSpread":0.00195,"preHourTrading":{"tag":"盘前","latestPrice":62.0224,"preClose":62.0224,"latestTime":"04:00 EDT","volume":1,"amount":62.0224,"timestamp":1789718420500,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":62.01,"preClose":62.0224,"latestTime":"19:30 EDT","volume":10,"amount":619.8306,"timestamp":1789687804886,"change":-0.0124,"changeRate":-0.0002,"amplitude":0},"volumeRatio":0.295943,"impliedVol":0.0863,"impliedVolPercentile":0.243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.295943,"shares":4700000,"dividePrice":1.5257,"high":62.1967,"amplitude":0.018327,"preClose":62.0224,"low":61.06,"week52Low":39.76,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.09,"committee":-0.626016,"eps":3.057033,"divideRate":0.024975,"volume":5818,"delay":0,"ttmEps":3.057033,"open":62.1967,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":60.7692,"twentyDayClose":62.111,"sixtyDayClose":55.6532},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665329027","title":"Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329027?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ROIV","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329008","title":"Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329008?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321399","title":"Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321399?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665218033","title":"Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2665218033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665218033?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","GDOC","FFOX","LFSC","LU0889565916.HKD","HELX","GNOM","BK4588","LU0109394709.USD","BK4551","BK4535","PTH","GH","BK4585","LU0320765992.SGD","BK4196","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106413707","title":"China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily","url":"https://stock-news.laohu8.com/highlight/detail?id=1106413707","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106413707?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:34","pubTimestamp":1788838468,"startTime":"0","endTime":"0","summary":"China Securities has released a research note indicating that the medical device sector maintained its revenue growth trajectory in Q2, with quarterly profit growth turning positive for the first...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","601066","GDOC","LGHT","PTH","RSPH","HART","IEIH","MDEV","BK1574","BK1583","BK1100","AGNG","MEDX","LNGR","09996","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155170383","title":"Medical Device Inspection Campaign Launched by Ningyang County Market Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=1155170383","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155170383?lang=en_us&edition=fundamental","pubTime":"2026-09-07 12:41","pubTimestamp":1788756073,"startTime":"0","endTime":"0","summary":"On September 7, enforcement officers from the Market Supervision Administration of Ningyang County, Shandong Province, visited retail pharmacies within their jurisdiction to conduct a targeted...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","BK1100","BK1583","PTH","09996","159883","LGHT","HART","IEIH","LNGR","MDEV","MEDX","GDOC","AGNG","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191894169","title":"MedTech Firm Joins Hong Kong Market: Evaluating MEDCAPTAIN's (02041) True Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1191894169","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191894169?lang=en_us&edition=fundamental","pubTime":"2026-09-07 12:18","pubTimestamp":1788754720,"startTime":"0","endTime":"0","summary":"As a wave of interim earnings reports floods in from medical device companies, the sector's recovery trajectory has become increasingly clear, with a definitive upward inflection point now visible in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","KCAI","RSPH","PTH","BK4588","BK1583","IEIH","BK4585","159883","02041","LNGR","GDOC","MDEV","BK1574","VXUS","LGHT","MEDX","BK1100","HART","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665692103","title":"Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665692103","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665692103?lang=en_us&edition=fundamental","pubTime":"2026-09-06 13:00","pubTimestamp":1788670818,"startTime":"0","endTime":"0","summary":"Roivant to present Phase 2 PHocus mosliciguat topline data in PH-ILD at ERS Congress Sept. 8, 2026Roivant flagged upcoming topline results from its Phase 2 PHocus study of mosliciguat in pulmonary hyp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDL92hcqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121796426","title":"Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796426?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:10","pubTimestamp":1788588618,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held September 4-6 in Chengdu, Sichuan, under the theme \"Enterprise Innovation and Cycle Crossing,\" Formatia Founder and CEO Peng Lei offered a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","MNTL","MDEV","BK1574","IBRN","MEDX","09996","IEIH","HART","159883","BK1583","RSPH","AGNG","BK1100","GDOC","LNGR","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","IBB","LABU","BK4585","MRNX","FFOX","MEDI","PINK","BBP","BK4535","FRTY","TBXU","PSCH","HELX","IDNA","BMED","XLVX","IEIH","EKG","GH","BK4551","PTH","RSPH","IYH","TECB","GNMX","SYNB","GDOC","BK4196","GNOM","LFSC","LU0109394709.USD","LU0889565916.HKD","BK4588","LU0320765992.SGD","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354794","title":"Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354794?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:10","pubTimestamp":1788559800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA7GZLSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","GH","GDOC","LU0109394709.USD","BK4585","LU0320765992.SGD","LU0889565916.HKD","PTH","EKG","GNMX","LFSC","BK4196","BK4535","BK4551","FFOX","GNOM","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802202","title":"Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802202?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:09","pubTimestamp":1788476991,"startTime":"0","endTime":"0","summary":"Axsome COO Mark Jacobson sells 10,000 shares for $2.09 millionAxsome Therapeutics COO Mark L. Jacobson exercised stock options for 10,000 common shares at $12.95 on Sept. 3, 2026.He sold 10,000 common","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLc9hvxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BK4007","BK4585","PTH","BK4505","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664049898","title":"Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2664049898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664049898?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:06","pubTimestamp":1788469582,"startTime":"0","endTime":"0","summary":"Immunovant holds annual stockholder meeting with 96% shares representedImmunovant held its annual shareholder meeting on Sept. 2, 2026.Shareholders backed the selection of Ernst & Young as independent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL364hlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4588","BK4585","BK4007","IMVT","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664704888","title":"Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664704888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664704888?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:10","pubTimestamp":1788444623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Teva Pharmaceutical ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","TEVA","LU2324357040.USD","LU1983299246.USD","IE0009355771.USD","LU0320765992.SGD","PTH","BK4584","BK4557","XBI","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4007","BK4559","LU0128526141.USD","BK4566","IE00BJJMRZ35.SGD","BK4596","IDNA","BK4588","IE0002141913.USD","LU0889565916.HKD","BBH","IE00BJT1NW94.SGD","BK4137","BK4581","HCSG","BK4139","BK4585","LABU","RVMD","CANC","IE0009354923.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121486923","title":"Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1121486923","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121486923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:00","pubTimestamp":1788422444,"startTime":"0","endTime":"0","summary":"The Yinchuan Municipal Market Supervision Administration in Ningxia is advancing a multi-pronged strategy to ensure the smooth implementation of the newly revised Medical Device Production Quality...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","BK1574","MEDX","159883","PTH","BK1583","IEIH","HART","09996","MDEV","RSPH","LNGR","BK1100","LGHT","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828323","title":"Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828323","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828323?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:25","pubTimestamp":1788398717,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines yesterday and set a price target of $315.00. Charles Zhu has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","IE00BJT1NW94.SGD","LU0109394709.USD","BBH","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","RVMD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","CANC","IE0009354923.USD","LU0889565916.HKD","PTH","IE0002141913.USD","BK4139","IE0009355771.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844659","title":"NEJM publishes Phase 1/2 clinical data on daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844659?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:55","pubTimestamp":1788386116,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) “announced that The New England Journal of Medicine has published a report describing data from the Phase 1/2 clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","BK4139","CANC","IE0002141913.USD","IE00BJJMRZ35.SGD","IDNA","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","RVMD","PTH","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD","IE00B2B36J28.USD","BBH","IE0009354923.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844613","title":"New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844613?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:50","pubTimestamp":1788385800,"startTime":"0","endTime":"0","summary":"Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) --  Revoluti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU2360107325.USD","BK4605","IE0009354923.USD","LU2298322129.HKD","IE00BJT1NW94.SGD","LU2487616109.SGD","LU1548497426.USD","PTH","RVMD","BK4588","LU1861220033.SGD","IE00BD6J9T35.USD","LU1978683503.SGD","IE00B4R5TH58.HKD","LU0124384867.USD","IE00BZ199S13.USD","NVIB","IE00B2B36J28.USD","L","BK4512","GDOC","BK4141","LU0109394709.USD","LU1983260115.SGD","IE0002141913.USD","LU1720051017.SGD","BK4107","ONX","BK4585","IE00BFTCPJ56.SGD","ON","CANC","LU1861219969.SGD","IE0009355771.USD","ONG","LU0053666078.USD","LU0348723411.USD","BBH","LU0889565916.HKD","IE00BFMHRM44.USD","LU2357305700.SGD","LU0320765992.SGD","IDNA","LU0724618433.USD","LU1854104046.USD","LU1854103824.USD","BK4139","LU1861215975.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664984906","title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664984906","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664984906?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:31","pubTimestamp":1788381115,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of common shares worth $11.21 millionRevolution Medicines director Lorence H. Kim sold 56,000 common shares on Aug. 31 at about $200.56–$206.15.Sa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1bnXL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","CANC","BBH","IE00B2B36J28.USD","IE0009355771.USD","RVMD","IDNA","IE00BJJMRZ35.SGD","LU0109394709.USD","PTH","LU0889565916.HKD","IE0009354923.USD","IE00BJT1NW94.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}